Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Curasight A/S said CEO Ulrich Krasilnikoff and CMO Prof. Andreas Kjær will hold investor and industry meetings in San Francisco during the J.P. Morgan Healthcare Conference week (Jan 12-15, 2026). Management will update on clinical progress, including the recent initiation of a Phase 1 uTREAT® trial in aggressive brain cancer and the ongoing Phase 2 uTRACE® prostate cancer trial conducted in partnership with Curium. The company emphasizes its uPAR theranostic platform—combining PET imaging (uTRACE) and targeted radioligand therapy (uTREAT)—as a differentiated diagnostic and treatment approach, though no near-term financial metrics were disclosed.

Analysis

Market structure: Near-term winners are Curasight (CURAS) and its partner Curium (partner/industrial OEM), plus isotope suppliers and PET imaging centers; losers are small diagnostic-only providers lacking a theranostic angle. The uPAR-focused theranostic niche can gain pricing power for companion diagnostics and targeted radioligands in uPAR-expressing tumors, but adoption will be supply-constrained (isotope manufacturing) and reimbursement-driven, capping upside until clear efficacy data arrive.

Risk assessment: Tail risks include Phase‑1/2 safety or efficacy failure, regulatory rejection, or a dilutive capital raise >€20–50m which would cut equity value by >20–30%; operational risk centers on Curium dependency and isotope supply bottlenecks (Lu‑177 or alternative radionuclide). Timing: immediate (Jan 12–15 JPM meetings) for sentiment swings; short-term 3–12 months for initial safety signals; long-term 12–36 months for pivotal data/commercial rollout. Key catalysts: JPM meetings (next 2 weeks), Phase‑1 safety readout (~6–12 months), Phase‑2 prostate data (~12–18 months).

Trade implications: Direct tactical play is a small, event-driven long in CURAS (2–3% portfolio) into JPM week with a tight stop and option hedge; hedge sector beta by shorting XBI or IBB (0.5–1% notional). If options available, buy 6–12 month call spreads to leverage upside while capping premium; scale out on any >30% pop and cut exposure on announcements of >€20m financing or negative safety signals.

Contrarian angles: Consensus optimism likely underestimates dilution and operational fragility — many early theranostic stories double on hype then collapse on readouts. Historical parallels (early radioligand pioneers) show binary outcomes; position sizing must be conservative and contingent on transparency around Curium terms and isotope supply contracts.

Key Decisions for Investors

• Establish a 2–3% long position in Curasight (CURAS) 0–5 trading days before the J.P. Morgan week to capture meeting-driven flow; set a hard stop-loss at -35% and an initial price target of +100% over 12 months contingent on positive early safety/efficacy signals.
• Buy a 6–12 month call spread on CURAS sized to 1% of portfolio (debit-limited structure) to gain asymmetric upside while capping premium; roll or take profit on any >50% implied move up or if Phase‑1 safety readout is neutral/negative.
• Short 0.5–1% notional of XBI (or hedge with IBB) to neutralize sector/systematic biotech beta while maintaining CURAS-specific exposure; adjust hedge ratio if CURAS outperforms by >20% in 2 weeks post-JPM.
• Exit or reduce CURAS position to zero if company announces a dilutive financing >€20–50m or issues press releases revealing lack of secured isotope supply; re-enter only after clear remediation (non-dilutive funding or contracted isotope capacity).